IDEAYA Biosciences, Inc. (IDYA) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $28.95: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 7.22; Below-average business quality.
IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the... Read more
Sell if holding. Engine safety override at $28.95: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 7.22; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 50. Score 4.5/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-13Recent Developments — IDEAYA Biosciences, Inc.
Latest news
- NEWS Ideaya Biosciences Enrolls First Patient In Its Phase 1 Trial Of IDE892 In Combination With IDE397 In Mtap-deleted Panc — benzinga Jun 15, 2026 positive
- NEWS Wedbush Reiterates Outperform on IDEAYA Biosciences, Maintains $58 Price Target — benzinga Jun 12, 2026 positive
- NEWS Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesd — benzinga Jun 9, 2026 negative
- NEWS Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket — benzinga Jun 9, 2026 neutral
- NEWS Reported Earlier, IDEAYA Biosciences Prices $300M Public Offering Of 5,555,556 Common Stock Shares And Pre-Funded Warran — benzinga Jun 9, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -62.2%. Quality floor flags this regardless of sector context.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $28.95: Quality below floor (1.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 5.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 7.22; Below-average business quality. Chart setup: Death cross but MACD improving, RSI 50. Prior stop was $26.95. Score 4.5/10, moderate confidence.
Take-profit target: $46.74 (+61.3% upside). Prior stop was $26.95. Stop-loss: $26.95.
Quality below floor (1.5 < 4.0).
IDEAYA Biosciences, Inc. trades at a P/E of N/A (forward -7.8). TrendMatrix value score: 6.2/10. Verdict: Sell.
25 analysts cover IDYA with a consensus score of 4.2/5. Average price target: $52.
What does IDEAYA Biosciences, Inc. do?IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs...
IDEAYA Biosciences is a clinical-stage precision oncology company developing small-molecule targeted therapies and ADCs for molecularly defined solid tumors, organized around synthetic lethality and DNA damage response mechanisms. Revenue is currently nil from product sales; the company funded primarily through an equity capital base and a $210M upfront from a Servier license for darovasertib outside the US. Nine product candidates are in clinical trials with darovasertib in Phase 2/3 uveal melanoma as the lead.